https://www.selleckchem.com/pr....oducts/defactinib.ht
Human epidermal growth factor receptor 2 (HER-2) is an established prognostic and predictive biomarker for breast cancer. To ensure accuracy and uniformity for HER-2 testing, ASCO/CAP published guidelines in 2007 which were updated in 2013 and recently in 2018. In this first study from Indian Oncology center, we evaluated the impact of 2018 ASCO/CAP guidelines. We found a substantial decrease in equivocal IHC cases (P-value less then .00001). On reclassification, a total of 5.6% cases from equivocal and positive categories (2013 guid
Like
Comment
Share
